Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor of the fungal enzyme Gwt1. Manogepix demonstrates broad spectrum in vitro activity against yeasts and molds, including difficult to treat pathogens. Because of its novel mechanism of action, manogepix retains potency against many resistant strains including echinocandin-resistant Candida and azole-resistant Aspergillus. Manogepix is also active against pathogens that demonstrate intrinsic resistance to other drug classes, such as Scedosporium, Lomentospora prolificans, and Fusarium with variable activity against Mucorales. Fosmanogepix demonstrates significant in vivo efficacy in mouse and rabbit disseminated infection models due to C. albicans, C. glabrata, C. auris, C. tropicalis, Coccidioides immitis, and F. solani as well as pulmonary infection models of A. fumigatus, A. flavus, S.prolificans, S. apiospermum and Rhizopus arrhizus. Clinical trials demonstrated high oral bioavailability (>90%), enabling switching between fosmanogepix intravenous and oral formulations without compromising blood levels. Favorable drug-drug interaction, tolerability, and wide tissue distribution profiles are observed making fosmanogepix an attractive option for the treatment of invasive fungal infections. This systematic review summarizes the findings of published data on fosmanogepix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 The mechanism of action of manogepix. Modified from 2019 Covel et al. [26]. Gwt1 is an enzyme which catalyzes an acyl group transfer reaction, an essential part of the GPI biosynthesis pathway. This occurs in the lumen of the endoplasmic reticulum. Gwt1 catalyzes the inositol acylation of glucosaminyl phosphatidylinositol (GlcN-PI), resulting in the formation glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), an intermediate in the biosynthesis of GPI anchors.](https://figures.cochat.ai/paper-figures/f5a1d5f19b404395b158e0a3c37f4275/fosmanogepix-a-review-of-the-first-in-class-broad-spectrum-agent-for-the-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fosmanogepix is a first in class Gwt1 fungal protein inhibitor, which is a class of proteins necessary for mannoprotein anchoring to the cell membrane and cell wall.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, with a wide tissue distribution, high oral bioavailability, and availability in both IV and oral formulations, FMGX provides drug characteristics that are favorable for treating invasive fungal infections, such as candidemia/invasive candidiasis caused by C. auris (24, 25).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“This novel mechanism provides a broad range of activity against Candida spp. including drug-resistant Candida.160”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Infections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Peter, O., & Menon, A. K. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700002-jlr200 · Cited by 403
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Ostrowsky, B., Greenko, J., Adams, E., Quinn, M., O’Brien, B., Chaturvedi, V., Berkow, E., Vallabhaneni, S., Forsberg, K., Chaturvedi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6901a2 · Cited by 246
Improved Outcome of Zygomycosis in Patients with Hematological Diseases?
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004) · Leukemia & Lymphoma · doi:10.1080/10428190310001653691 · Cited by 227
In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Research works printed but not linked: 4
- Hata, K., Hori, T., Miyazaki, M., and Watanabe, N. (2011, January 17–20). In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, F1–1377. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
- Horii, T., Okubo, M., Miyazaki, M., Hata, K., and Watanabe, N.-A. (2010, January 12–15). In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. F1–843. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA.
- Petraitis, V., Petraitiene, R., Maung, B.B.W., Mansbach, R., Shaw, K.J., and Walsh, T.J. (2018, January 21–24). Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model. Proceedings of the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018), Madrid, Spain.
- Watanabe, N.-A., Horii, T., Miyazaki, M., and Hata, K. (2011, January 17). In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals. Proceedings of the F1–1378, in Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA.
Cited by
Items 101–200 of 228
Hodges, M. R., Hazel, S., Kramer, W. G., van Hoogdalem, E., van Marle, S., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01455-23 · Cited by 13
Invasive Aspergillosis in the Intensive Care Unit
Zubovskaia, A., & Vázquez, J. A. (2025) · Journal of Fungi · doi:10.3390/jof11010070 · Cited by 14
Cerebral Aspergillosis: Diagnostic Challenges, Therapeutic Strategies, and Future Research
Chantelot, L., Sitterlé, E., Poirée, S., Jullien, V., Danion, F., & Serris, A. (2025) · CNS Drugs · doi:10.1007/s40263-025-01241-0 · Cited by 13
Breaking down the wall: Solid-state NMR illuminates how fungi build and remodel diverse cell walls
Gautam, I., Ankur, A., Singh, K., Jacob, A., Doering, T. L., Gow, N. A. R., Latgé, J., & Wang, T. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013678 · Cited by 14
Squitieri, D., Rizzo, S., Torelli, R., Mariotti, M., Sanguinetti, M., Cacaci, M., & Bugli, F. (2025) · Pharmaceuticals · doi:10.3390/ph19010008 · Cited by 12
Focused library of phenyl-fused macrocyclic amidinoureas as antifungal agents
Balestri, L. J. I., D’Agostino, I., Rango, E., Vagaggini, C., Marchitiello, R., Mariotti, M., Casian, A., Deodato, D., Truglio, G. I., Orofino, F., et al. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10388-7 · Cited by 12
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia
Bels, D. D., Maillart, E., Bambeke, F. V., Redant, S., & Honoré, P. M. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2142207 · Cited by 12
Azole resistance in Aspergillus species: promising therapeutic options
Pasula, S., & Chandrasekar, P. H. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1940134 · Cited by 14
Hodges, M. R., Ople, E., Evans, P., Pantophlet, A. J., Richardson, J. M., Williams, D., Tripathy, S., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00273-24 · Cited by 11
Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field
Stafylidis, C., Diamantopoulos, P. T., Athanasoula, E., Solomou, E. E., & Anastasopoulou, A. N. (2022) · Journal of Fungi · doi:10.3390/jof8111127 · Cited by 14
Antifungal Stewardship Interventions in Patients with Hematologic Malignancies
Vergidis, P. I., Stevens, R. W., & Agrawal, S. G. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00465-1 · Cited by 11
Verhasselt, H. L., Thissen, L., Scharmann, U., Dittmer, S., Rath, P., Steinmann, J., & Kirchhoff, L. (2025) · Mycopathologia · doi:10.1007/s11046-025-00941-x · Cited by 10
Hodges, M. R., van Marle, S., Kramer, W. G., Ople, E., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01650-23 · Cited by 11
Guo, M., Xu, H., Yan, Z.-Z., Wang, X., Su, X., Guo, C., Hou, Z., & Gong, P. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133859 · Cited by 10
A Review of Current Insights in Fungal Endocarditis
Akritidou, O., Peristeri, A.-M., Lymperatou, D., Prokopidou, A., Christaki, E., & Nikopoulou, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176149 · Cited by 10
Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment
Castro-Fuentes, C. A., Cabrera-Guerrero, J. P., Duarte-Escalante, E., Hernández‐Silva, G., Herrera, A. C., & Reyes-Montes, M. D. R. (2026) · Journal of Fungi · doi:10.3390/jof12030229 · Cited by 10
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 11
Antifungal chemotherapies and immunotherapies for the future
Armstrong-James, D. P. H. (2022) · Parasite Immunology · doi:10.1111/pim.12960 · Cited by 10
An Update on Recent Clinical Trial Data in Bloodstream Infection
Stewart, A. G., Simos, P., Sivabalan, P., Escolà‐Vergé, L., Garnham, K., & Isler, B. (2024) · Antibiotics · doi:10.3390/antibiotics13111035 · Cited by 9
Current strategies in design and synthesis of antifungals hybrid and chimeric diazine derivatives
Diaconu, D., Savu, M., Ciobanu, C. I., Mangalagiu, V., & Mangalagiu, I. I. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118069 · Cited by 10
Chakraborty, S., Rahate, K., Kumar, C., & Idicula‐Thomas, S. (2022) · Drug Development Research · doi:10.1002/ddr.22015 · Cited by 8
Chen, Y.-Y., Gao, F., Chen, X., Tao, S., Chen, P., & Lin, W. (2024) · mSphere · doi:10.1128/msphere.00619-23 · Cited by 8
Shaheen, S. K., Juvvadi, P. R., Allen, J., Shwab, E. K., Cole, D., Asfaw, Y. G., Kapoor, M., Shaw, K. J., & Steinbach, W. J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00682-21 · Cited by 9
Self-citationKline, A., & Lionakis, M. S. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02368-21 · Cited by 8
Xiao, P., Sahu, P., Pfaff, S. A., Ankur, A., Ranasinghe, Y. K., Gow, N. A. R., Latgé, J., Cosgrove, D. J., & Wang, T. (2025) · The Cell Surface · doi:10.1016/j.tcsw.2025.100159 · Cited by 9
Insights into the role of sphingolipids in antifungal drug resistance
Kalra, S., Tanwar, S., & Bari, V. K. (2023) · Fungal Biology Reviews · doi:10.1016/j.fbr.2023.100342 · Cited by 8
Fusarium species central nervous system infection
Strong, N., & Ostrosky-Zeichner, L. L. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001009 · Cited by 8
Konings, M., Eadie, K., Strepis, N., Nyuykonge, B., Fahal, A. H., Verbon, A., & van de Sande, W. W. J. (2023) · Medical Mycology · doi:10.1093/mmy/myad118 · Cited by 9
Therapeutic advances in neuroinfectious diseases
Ardakani, R. V., Jia, L., Matthews, E., & Thakur, K. T. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241274246 · Cited by 8
Exploring therapeutic strategies for candidiasis: From current treatments to future perspectives
Kantroo, H. A., Mubarak, M. M., & Ahmad, Z. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108797 · Cited by 7
Infection caused by Candida auris: state of the art
Marena, G. D., Carvalho, G. C., Monazzi, L., Maschio-Lima, T., Almeida, M. D., Silva, J. D., Fortunato, G., Araújo, V., Venancio, D. C. V., Chang, M., et al. (2022) · Mycosphere · doi:10.5943/mycosphere/13/1/10 · Cited by 6
Latin American Plants against Microorganisms
Cuevas-Cianca, S. I., Romero-Castillo, C., Gálvez-Romero, J. L., Sánchez-Arreola, E., Juárez, Z. N., & Hernández, L. R. (2023) · Plants · doi:10.3390/plants12233997 · Cited by 7
Future Directions for Clinical Respiratory Fungal Research
Armstrong-James, D. P. H. (2021) · Mycopathologia · doi:10.1007/s11046-021-00579-5 · Cited by 7
Brent, G., Abdul‐Wahab, A., Borman, A. M., Ferguson, L., Ferreras-Antolin, L., Ho, B. C. S., Johnson, E. M., Mashhoudi, Y., Rijswijk, E. V., Wijesuriya, N., et al. (2022) · Pediatric Dermatology · doi:10.1111/pde.15179 · Cited by 6
Farnesol functionalized chitosan-gold nanocomposites for disruption of fungal biofilms
Kumar, A., Yadav, E., Yadav, B., Nanda, D., Meena, A. S., Yadav, S. P. S., Poluri, K. M., & Gupta, P. (2025) · Materials Today Chemistry · doi:10.1016/j.mtchem.2025.103079 · Cited by 5
New and emerging drugs for the treatment of invasive fungal infections
Maves, R. C., & Fowler, M. N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2568547 · Cited by 5
Drug Discovery and Repurposing for Coccidioides: A Systematic Review
Saeger, S., Lozano, S., Wiederhold, N. P., Yu, J., Lopez-Ribot, J. L., & Hung, C.-Y. (2025) · Journal of Fungi · doi:10.3390/jof11120875 · Cited by 5
New Perspectives on Antimicrobial Agents: Fosmanogepix
Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 6
Mechanisms of antifungal resistance
Delgado, J., Núñez, F., Bermúdez, E., & Asensio, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00156-8 · Cited by 7
An update on pharmacotherapy for fungal infections in allogeneic stem cell transplant recipients
Panagopoulou, P., & Roilides, E. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2387686 · Cited by 6
Timotheous, R., Naz, H., Arif, U., Dar, M. T., Sarwar, M. F., Awan, M. F., Ali, S., & Rab, S. O. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-024-10400-5 · Cited by 5
Lewis, R. E., & Wiederhold, N. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-35803-6_8 · Cited by 5
Current and emerging therapies for fungal biofilms and systemic infections
Elgammal, Y., Martinez, R. I. G., Requejo, A., & Martinez, L. R. (2025) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2570185 · Cited by 4
Chastain, D. B., Anderson, D. T., Eudy, J., Henao‐Martínez, A. F., & Cluck, D. B. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag055 · Cited by 5
Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program
Cohen, S. H., Allyn, P. R., Chow, F. C., Rathe, J., Nanayakkara, D. D., Hutfles, G., Vijayan, T., Smith, E. A., Saling, C. F., Ilges, D., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag271 · Cited by 6
Comparative genomics predict specific genes in potential mucorales identification
Zhang, M., Xu, W., Mei, H., Song, G., Ge, N., Tao, Y., Liu, W., & Liang, G. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03659-w · Cited by 4
Prodrugging fungicidal amphotericin B significantly decreases its toxic effects
Štěpánek, O., Parigger, M., Procházková, E., Čmoková, A., Kolařík, M., Dračínská, H., Černá, V., Kalíková, K., Grobárová, V., Černý, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117157 · Cited by 6
Significance of immunotherapy for human fungal diseases and antifungal drug discovery
Mir, M. A., Jan, U., & Qadri, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96127-1.00001-2 · Cited by 5
Almeida‐Silva, F., Marques, F. P. N., Tenório-Alvarenga, P. H., Poester, V. R., Xavier, M. O., Zancopé‐Oliveira, R. M., & Almeida‐Paes, R. (2025) · Brazilian Journal of Microbiology · doi:10.1007/s42770-025-01711-z · Cited by 3
Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm
Morena, R., Morrone, H. L., Serapide, F., & Russo, A. (2025) · Diagnostics · doi:10.3390/diagnostics16010034 · Cited by 3
Kaur, A., Sharma, K., Sharma, N., & Aggarwal, G. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265282411240119061441 · Cited by 3
New Antifungal Drugs: Discovery and Therapeutic Potential
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 6
Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps
Kourti, M., & Roilides, E. (2024) · Mycopathologia · doi:10.1007/s11046-024-00896-5 · Cited by 3
New Antimycotics in the Pipeline – For Ophthalmology Too? A Short Review
Behrens‐Baumann, W. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1478-4248 · Cited by 3
Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients
Cabrera, N. L., George, I. A., Rauseo, A. M., Mazi, P. B., & Spec, A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000995 · Cited by 3
Antifúngicos: lo que tenemos, lo que tendremos, lo que queremos.
Martínez-Méndez, D., Bravo-Acosta, M., & Semprún-Hernández, N. (2023) · Investigación Clínica · doi:10.54817/ic.v64n4a11 · Cited by 1
How can we optimize antifungal use and stewardship in the treatment of acute leukemia?
Taynton, T., Allsup, D. J., & Barlow, G. D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383401 · Cited by 2
Cooper, R. J., Arif, S., Baker, A. W., Wiederhold, N. P., Sarantopoulos, S., Iftikhar, M., Stanly, K., Collis, B. J., Ni, B., Sim, B., et al. (2026) · ASM Case Reports · doi:10.1128/asmcr.00189-25 · Cited by 2
Novel antifungal compounds against Fusarium spp: A systematic review
de León, N. A., Álvarez‐Villalobos, N. A., Gonzalez, G. H., Treviño‐Rangel, R. D. J., & Montoya, A. M. (2026) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimc.2026.503109 · Cited by 2
Disseminated Fungal Infection in Profoundly Immunocompromised Hosts: A Three-Case Series
Wang, A., & Greene, J. (2026) · Cureus · doi:10.7759/cureus.104022 · Cited by 2
Rux, C. E., Johnson, M. D., Grant, V. C., Katipunan, S. G., Chahine, E. B., Smith, D. J., Lockhart, S. R., Drwiega, E. N., Gubbins, P. O., & author, S. A. A. C. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70122 · Cited by 3
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 3
Gowtham, L., Meghana, Y., Mannangatty, T., Vasavi, S., Nirmal, J., Bagga, B., Garg, P., Mishra, D., & Roy, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.4.49 · Cited by 2
Athni, T. S., Strauch, C. B., Kovac, V., Arbona‐Haddad, E., Pérez, I., Gupta, S., Aleissa, M. M., Liakos, A. D., Tong, A., Vedula, R. S., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag304 · Cited by 2
Alsarra, I. A., Chikhale, R. V., Al-Mohizea, A. M., & Islam, M. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114767 · Cited by 2
Wiederhold, N. P., Patterson, H. P., Sanders, C. J., & Cañete-Gibas, C. F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-26 · Cited by 2
Zeoli, A., Shieh, C., Bloch, K. C., Tao, L., Mainor, A., Cimino, C., Zeches, B., & Chiang, A. D. (2026) · ASM Case Reports · doi:10.1128/asmcr.00033-26 · Cited by 2
Disseminated Scedosporium infection in the early post‐kidney transplant period
Rao, M., Casias, M., & Abidi, M. Z. (2024) · Transplant Infectious Disease · doi:10.1111/tid.14232 · Cited by 2
Weng, T.-P., Wang, S.-W., Lo, S.-T., Su, S.-L., Hsieh, M., Tsai, P.-J., Tsai, P.-F., Wu, C., Lee, N., Ko, W., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02117-24 · Cited by 2
Nakaseomyces glabrata endocarditis: A therapeutic dilemma
Jim, K. K., Daems, J. J. N., Boekholdt, S. M., & van Dijk, K. (2023) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2023.04.002 · Cited by 3
Special Issue: Antifungal Agents Recently Approved or under Development
Espinel‐Ingroff, A., & Dannaoui, É. (2021) · Journal of Fungi · doi:10.3390/jof7030239 · Cited by 2
Hagras, M., Ezzat, H. G., Abuelkhir, A. A., & Mayhoub, A. S. (2025) · RSC Advances · doi:10.1039/d5ra00499c · Cited by 1
Ramage, G., Kean, R., Mackay, W. G., Vaccaro, A., Lopez-Ribot, J. L., & Howe, M. H. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_7 · Cited by 2
Raman, E., & Sharma, S. (2025) · Cureus · doi:10.7759/cureus.87716 · Cited by 1
Bhaimia, E., Russell, D., & Santos, C. A. Q. (2025) · ASM Case Reports · doi:10.1128/asmcr.00087-25 · Cited by 2
Exploring New Antifungal Agents for the Treatment of Candida Infections in the Era of Resistance
Bhatol, J., Dwivedi, S., Jain, V. K., Sisodiya, N., & Darwhekar, G. N. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3448 · Cited by 1
Marena, G. D., Carvalho, G. C., Magalhães, M. H. C., Figueiredo, J., Ramos, D. H., Nosanchuk, J. D., & Taborda, C. P. (2026) · Journal of Fungi · doi:10.3390/jof12030162 · Cited by 1
Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis
Vega, P., Bhattacharyya, P., Lieberman, J. A., Kuczmarski, T. M., Yoke, L. H., So, L. M., Smith, H. Z., Lengermann, R., Cohen, S., Fredricks, D. N., et al. (2026) · Transplant Infectious Disease · doi:10.1111/tid.70203 · Cited by 1
Negi, P., Verma, N., Rishi, P., Multani, K., Sharma, M., Kumari, S., & Raj, K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04864-z · Cited by 1
Non-Candida fungal cholecystitis - an uncommon occurrence even in the right host
Dumais, M. G., Czech, M. M., Hyder, M. A., Lee, R. R., Gea‐Banacloche, J., Kanakry, C. G., Kim, S. A., Adhikari, B., Surette, M. D., Zelazny, A. M., et al. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05541-1 · Cited by 2
Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1
Mansour, M. A., Wahid, M. M., Molla, M. A. S. E., Helmy, M. H., Adel, T. M., & Mostafa, H. N. (2026) · Mycoses · doi:10.1111/myc.70214 · Cited by 1
Finkina, E. I., Shevchenko, O. V., Gerasimova, А. А., Fateeva, S. I., Баландин, С. В., & Ovchinnikova, T. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188141 · Cited by 1
Promising antimycotics for the treatment of invasive infections
Ortenberg, E. A. (2023) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2023.2.165-170 · Cited by 2
Sharma, S. M., Sharma, R., & Chandrateya, P. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265317733241021190116 · Cited by 1
Metabolic sensing tips the balance of drug tolerance in fungal meningitis
Mottola, A., Hartl, J., Ralser, M., & Berman, J. G. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01595-5 · Cited by 1
Aspergillus- Human Interactions: From the Environment to Clinical Significance
Thammahong, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98509 · Cited by 2
[Histochemical studies of glial cells irradiated in vitro with a dose of 5,000 gamma rays].
Ostenda, M. (1972) · PubMed
Winter, C., Siepe, I., Wise, A., Dorali, A., Barrett, A. G. M., & Witschel, M. C. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00497 · Cited by 1
Headaches in a Horseback Rider
Hunter, N., Kostowniak, C., Hamayel, A., Bliss, A., Lakin, H., Tan, J. N. M., & Proia, L. A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad145
Antifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Lewis, R. E., & Stanzani, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00474-0
Butassi, E., Svetaz, L. A., & Sortino, M. A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815049428123010008
Progress in the Development of Fungal Metabolites as New Drugs for Human Mycoses
Takahashi, J. A. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_15 · Cited by 2
Potential targets for the development of antifungal drugs
Nadeem, A. Y., Shehzad, A., Shahzad, R., Aljafary, M. A., & Al-Suhaimi, E. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18866-4.00013-4
Lockhart, S. R., & Berkow, E. L. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0133
Lockhart, S. R., & Berkow, E. L. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0133
Novel Therapeutic Approaches to Control Fungal Biofilms
Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11
Massey, J., Haidar, G., Shields, R. K., & Tyne, D. V. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001214
Understanding Fungal Pathogens and Their Challenges in Therapy
Kamran, M., Habib, M. B., Zafar, S., Shahid, A., Ali, M., & Shaikh, R. S. (2025) · Springer eBooks · doi:10.1007/978-3-032-01356-9_8
Trends in compassionate use of medicinal products: Israel 2020–2024
Schwartzberg, E., Marom, E., Finkel-Pekarsky, V., Shani, S., Cohen-Kandli, M., & Aboukaoud, M. (2025) · Israel Journal of Health Policy Research · doi:10.1186/s13584-025-00730-3
Metadata
- Authors
- Shaw, K. J., & Ibrahim, A. S.
- Affiliations
- Hearts Consulting Group, LLC, Poway, CA 92064, USA
- University of California, Los Angeles (US)
- Corresponding author
- Shaw, Karen Joy
- Ibrahim, Ashraf S.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-10-22
- Volume
- 6
- Issue
- 4
- Pages
- 239
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC7711534
- OpenAlex
- W3093555016
- Cited by
- 229
- References
- 64
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 36 · 2023: 47 · 2022: 30 · 2021: 25
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- fosmanogepix, manogepix, invasive fungal infections, antifungal drug development, Candida, Aspergillus, echinocandin resistance, azole resistance, Scedosporium, Lomentospora prolificans, Fusarium, Mucorales, oral bioavailability, drug-drug interactions, drug tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.